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ABSTRACT
In pretransplantation therapy busulfan is typically given every 6 hours. We infused busulfan once daily at 130
mg/m2 for 4 days, performing pharmacokinetic analyses on plasma concentration-time data (n  60 patients)
on days 1, 3, and/or 4. Mean (percent coefficient of variation) maximum concentration, volume of distribution,
half-life, and clearance were 3.6 g/mL (13.8%), 22.6 L/m2 (20.2%), 2.73 hours (27.5%), and 109 mL/min/m2
(26%), respectively. The mean (percent coefficient of variation) and median daily areas under the curve were
4873 (21.8%) and 4871 M  minute. Intrapatient variability in day-to-day estimated clearance was <20%,
without day-to-day drug accumulation. The pharmokinetic parameters were compared with those from 47
patients given intravenous busulfan at 0.8 mg/kg (32 mg/m2) every 6 hours. We conclude that there is (1)
a dose proportionality based on mean and median areas under the curve, (2) unchanged estimated clearance
with a 4-fold increase in dose and a 2.5-fold difference in dosing rate, (3) negligible variability in dose-to-dose
pharmacokinetics and negligible interdose accumulation with once-daily administration, and (4) no change in
pharmokinetic parameter(s) with concomitant use of imidazole antifungals, oral contraceptives, or phenytoin.
In summary, intravenous busulfan has highly predictable, linear pharmacokinetics from 32 mg/m2 (0.8
mg/kg) to 130 mg/m2 (3.2 mg/kg). Further, once-daily intravenous busulfan dosing is convenient, favoring its
more widespread application.
© 2007 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Busulfan (Bu) as an alternative to total body irra-
iation in pretransplantation conditioning therapy has
ecome increasingly popular over the past several
ears [1-3]. For many years only an oral Bu dosage
orm was available. In high-dose chemotherapy, in
hich precise dose delivery is of utmost importance
or treatment safety, this conferred a distinct disad-
antage [4]. To improve treatment safety and efﬁcacy
ith more precise delivery of oral Bu, different steps
ere suggested, including empirically divided (every
-hour) dosing and individualized dose delivery based a
6n Bu pharmacokinetics (PK) [5-10]. The value of
uch PK-directed oral Bu dosing was not uniformly
ccepted, and the value and reproducibility of PK-
uided oral Bu dosing has been questioned [11,12].
owever, the introduction of a parenteral Bu formu-
ation [13-15] allowed more precise dose delivery and
ermitted the systematic exploration of new dosing
chedules in conditioning therapy for hematopoietic
tem cell transplantation (HSCT) [16-19]. Two of the
ost important objectives during new drug develop-
ent are the determination of optimal drug dose and
chedule. This will ensure the safe delivery of the
gent, thus increasing the probability of a beneﬁcial
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Once-Daily IV Busulfan in Pretransplantation Conditioning Therapy 57herapeutic outcome and minimizing the likelihood of
erious toxicity.
The initial clinical studies with intravenous (IV)
u were performed with the every 6-hour Bu dosing
rogram previously established with the oral formu-
ation [14,15]. However, shortly after regulatory ap-
roval, we initiated clinical studies in patients with
cute myeloid leukemia (AML) and myelodysplastic
yndrome (MDS) using a regimen of IV Bu adminis-
ered over 3 hours once daily (QD) for 4 days, with
ach dose preceded by ﬂudarabine [19].
This regimen was extremely well tolerated, and as
art of the clinical transplantation study, a PK inves-
igation of once-daily Bu was performed to (1) deﬁne
he PK proﬁle of (high-dose) Bu administered IV QD
or 4 days; (2) conﬁrm if the previously reported linear
u PK proﬁle in oral doses from 2 mg up to 1.0 mg/kg
ody weight [20] (parenteral equivalent to 1 mg/kg
eing 0.8 mg/kg or 32 mg/m2) [14,15] would be
bserved with doses of 130 mg/m2 (3.2 mg/kg per
ose) given IV QD; (3) discern possible differences in
he PK parameterization in QD Bu versus an every
-hour Bu schedule; (4) elucidate the population vari-
bility of Bu PK for QD versus every 6-hour (IV)
dministration; and (5) review the possible inﬂuence
f concomitant administration of other drugs on the
K disposition of Bu given in the QD schedule.
ETHODS
atient Selection
To be eligible for these programs, patients with
ML and MDS could not qualify for treatment pro-
ocols of higher institutional priority. These patients’
nitial conventional induction chemotherapy had failed
r they had certain high-risk disease features in ﬁrst or
ubsequent complete remission. Subjects with MDS
ere eligible if they had a high International Prog-
ostic Score System score (2) or if they progressed
fter chemotherapy [19].
The eligibility criteria also included normal (or
ith minor deviation, considered “not to be of clinical
igniﬁcance”) renal and hepatic functions, with alanine
minotransferase level 3 times the upper normal
imit; a ZUBROD performance status score 2; neg-
tive serology for hepatitides B and C and human
mmunodeﬁcient virus; a left ventricular ejection frac-
ion 45%; forced expiratory volume in 1 second,
orced vital capacity, and DLCO 50%; absence of
uncontrolled) infection; and no chemotherapy within
0 days before study entry. An HLA antigen-compat-
ble related or unrelated donor was required. All pa-
ients signed an informed consent in accordance with
nstitutional guidelines. One patient was treated ac-
ording to the QD administration protocol under a
compassionate plea” mechanism due to chronic renal aailure. This patient was included in the analysis after
nstitutional review board approval.
onditioning Regimen
The QD treatment program was described by de
ima et al [19] and consisted of ﬂudarabine 40 mg/m2
iven over 60 minutes daily for 4 days, with each dose
mmediately followed by IV Bu 130 mg/m2 over 3 hours
aily (days 6 to 3). Patients with a 1-antigen mis-
atched related or a matched unrelated donor received
ntithymocyte immunoglobulin (thymoglobulin) on
ays 3 to 1, 0.5 mg/kg on day 3, 1.5 mg/kg on
ay 2, and 2.0 mg/kg on day 1. Day 0 was the day
f transplantation.
The 4-times daily, ie, every 6-hour, administration
chedule was modiﬁed from Tutschka et al [3], and
escribed in detail by Andersson et al [15]: Bu was
dministered at 0.8 mg/kg body weight IV over 2
ours every 6 hours for 16 doses followed by cyclo-
hosphamide Cy at 60 mg/kg IV over 1 hour for 2
oses on 2 consecutive days. After a day of rest, HSCT
as performed.
The IV Bu was diluted in normal saline to 0.5
g/mL and infused via a controlled-rate infusion
ump through a central venous catheter. The Bu
oses were calculated based on the lower of actual or
deal body weight; for patients who were20% above
heir ideal body weight, the dose was based on ad-
usted ideal body weight.
The ﬁnal Bu “administration solution” was stable
or 8 hours at room temperature and for 12 hours if
efrigerated (data on ﬁle, PDL BioPharma, Inc., Fre-
ont, Calif). The IV Bu formulation used in this trial
as Busulfex (Bu for injection; PDL BioPharma, Inc.)
nd has been previously described [13,14].
upportive Care
Phenytoin was used in all patients during and 1 day
fter completion of IV Bu therapy, starting the evening
efore or in the morning of the ﬁrst Bu dose. All other
upportive care measures, including blood products and
rophylactic antibiotics, were used according to extant
nstitutional protocols. Voriconazole and itraconazole,
hen used for diagnosed or presumed fungal infec-
ion, was stopped before admission for treatment on
hese protocols. Due to the long half-life of the azole
rugs, patients were considered as taking the respec-
ive azole derivative if they had been receiving it for
1 week and had stopped it within the previous week
efore admission for transplantation. Contraceptive
gents were used in females of fertile age at the dis-
retion of the attending physician; the drugs used
ere Lo Ovral, Ortho-TriCyclen, Premarin, Prem-
ro, and Provera. Due to the previously reported
nfavorable interactions between Bu and imidazole
ntifungal agents [21], estrogen/progestins [22], met-
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T. Madden et al.58onidazole [23], and phenytoin [24], all concomitant
edications preceding and during the pretransplanta-
ion conditioning period were recorded and their pos-
ible inﬂuence on Bu PK assessed separately.
usulfan Sample Collection and Analysis
Blood samples for each Bu schedule were obtained
s follows.
Once-daily schedule. Blood samples (5 mL collected
n heparinized glass Vacutainer tubes) for Bu plasma
oncentration determination were collected before
dministration of the drug and at 15, 90, and 175
inutes (5 minutes before the end of infusion) after
he start of the ﬁrst dose. Samples were also obtained
t 15 and 30 minutes and at 1, 2, 4, 6, 8, 10, and 21
ours after the end of infusion (just before starting the
ext daily dose). This sampling schedule was repeated
fter the third and/or fourth dose whenever possible.
Every 6-hour schedule. Blood samples (5 mL col-
ected as described above were collected in conjunc-
ion with the ﬁrst, ﬁfth and ninth (steady-state) Bu
nfusions [15]; immediately before drug infusion
trough) and at 15, 30, and 45 minutes after the start
f infusion, at 5 minutes before the end of infusion
“peak” or “end of infusion”), and at 15, 30, 60, 120,
80, and 240 minutes after the end of the infusion. In
ddition, a sample was taken immediately before the
3th infusion (“trough”) and 5 minutes before its
ompletion (“peak”).
In each study all blood samples were collected
rom a peripheral IV line to avoid probable sample
ontamination caused by the proximity between the
ifferent ports of the central venous catheter. All sam-
les were immersed in melting ice, carried to the
aboratory, and after separation in a refrigerated cen-
rifuge the plasma was cryopreserved at 70°C until
nalysis by using a validated high-performance liquid
hromatographic analytical method with a lower limit
f quantiﬁcation of 25 ng/mL [12,14].
harmacokinetic Analyses
Bu peak concentrations (Cmax) and the corre-
ponding peak time were observed values. The area
nder the plasma concentration versus time curve
AUC) per Bu dose was calculated by dividing the
dministered drug dose by the ﬁnal plasma clear-
nce estimate, and the plasma clearance was deter-
ined by modeling all plasma concentration versus
ime data for each patient. Parameters such as vol-
me of distribution of the central compartment,
limination rate constant, and microconstants were
rimary parameters derived from model estimates,
hereas steady-state volume of distribution, half-
ives, and clearance were calculated from the pri-
ary parameters.
Initially, various compartmental models were ﬁt to pach patient’s Bu concentration-time data by using
aximum likelihood estimation. Model selection was
etermined using the Akiake information criteria, vi-
ual inspection, and statistical estimation of (goodness
f) ﬁt. The PK modeling was performed using the
DAPT II 4.0 (BMRS, University of Southern Cali-
ornia, Los Angeles, Calif) [25].
PK parameters were estimated using the plasma
oncentration versus time data obtained separately for
ach individual dose and collectively for the data ob-
ained over the entire 4-day treatment period. The
eported PK parameters are the ﬁnal estimates ob-
ained using individual patient data acquired over the
-day interval.
To detect the possible inﬂuence of concomitant
edications on Bu PK, a univariate correlation was
ade between patients who had taken such medica-
ions (itraconazole/voriconazole, contraceptives) ver-
us those who had not relative to the average clearance
nd AUC values of Bu for the 4-day treatment course
n the QD treatment group.
Because all patients received phenytoin, the pos-
ible inﬂuence of phenytoin on Bu PK was assessed in
slightly different way; First, we compared day 1 Bu
learance and AUC between patients who started phe-
ytoin immediately before (ie, within 1 hour, or “the
orning of”) the start of Bu administration versus
hose who started phenytoin the evening before Bu
12 hours before starting Bu). Second, we compared
he clearance and AUC estimates for day 1 of these
ubgroups with the data obtained on day 3 or 4 of Bu
dministration.
ESULTS
nce-daily Busulfan Pharmacokinetics
From February 2001 to July 2003, 94 patients met
ligibility requirements and were enrolled in the QD
u trial. Complete Bu plasma concentration time data
ere obtained in 60 patients (demographics presented
n Table 1); 30 remaining patients declined blood
ampling and in 4 patients an insufﬁcient number of
lood samples was obtained.
Table 2 outlines the mean population PK param-
ters obtained by modeling the plasma concentration
ersus time data obtained in each patient over the
-day course. In each case a 1-compartment open
odel best described the measured Bu plasma con-
entration time data. The mean Bu clearance in this
roup was 109 mL/min/m2, with a coefﬁcient of vari-
tion 26% and a range of 59 to 180 mL/min/m2.
his mean clearance value is similar to the mean and
edian clearance values reported in previous adult
tudies in which IV Bu was delivered at a dose of 0.8
g/kg over 2 hours every 6 hours [14,15]. Other
arameters such as the geometric mean plasma half-
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Once-Daily IV Busulfan in Pretransplantation Conditioning Therapy 59ife (2.7  0.9 hours) and volume of distribution (22.6
4.5 L/m2) were also very similar to those reported
n studies in adults in which Bu was given 4 times daily
ntravenously [15] or orally [20].
The Bu plasma concentrations versus time pat-
erns were consistent with repeated dosing, regardless
f administration schedule, except there was no accu-
ulation noted with the QD regimen, whereas, as
xpected, some accumulation was recorded with the
very 6-hourly administration (for representative ex-
mples, see Figure 1a,b), with steady state typically
eing achieved by dose 3. The mean day 1 Cmax, after
he daily 3-hour infusion, was 3.6 g/mL (coefﬁcient
f variation 15%; Figure 2) and remained consistent
etween days, with a mean Bu Cmax on treatment days
and 4 of 4.2 g/mL (coefﬁcient of variation 15%).
he intraindividual difference in between-day Bu
max within patients deviated, on average, 8%. The
aximum single observed span between day 1 and day
or 4 Cmax in an individual patient was 23%. The
edian Bu Cmax after QD IV administration at a dose
f 130 mg/m2 was3 times higher than that observed
ith 4-times daily IV dosing at 0.8 mg/kg. This would
e expected because the Bu delivery rate on the QD
chedule was about 2.5 times greater than when the
rug was given every 6 hours (3- versus 2-hour infu-
ion).
The use of a QD Bu schedule did not result in
ny drug accumulation over the 4 days, with the
able 1. Patient Characteristics
Demographic
Characteristics
QD Protocol Q 6-Hour Protocol
n  60 n  47
edian age, (range) 44 (13-65) 51 (18-68)
eight (kg) 75 (50-135) 82 (47-140)
eight (cm) 169 (150-188) 173 (152-183)
ender
Females 29 20
Males 31 27
ace
Asian 1 1
Black 5 4
Hispanic 10 8
White 44 34
nderlying disease
AML 48
MDS 12
CML 47
able 2. Comparison of Mean Population PK Parameters Between Two D
Pharmacokinetic
Parameter
Once Daily Bu
(n  60) (CV %)
max (g/mL) 3.6 (14)
d (L/m2) 22.6 (20)
learance (mL/min/m2) 109 (26)
1/2 (hour) 2.7 (27)
UC (M  min) 4,873 (22)nterday AUC in each subject varying by 15%
Figure 3). This degree of variability is similar to
hat has been observed previously using IV Bu 4
imes daily [15]. Systemic exposure, represented by
UC, with QD Bu administration was 4 times
hat obtained with the every 6-hour schedule (Table
and Figure 4).
The possible effects of using concomitant medi-
ations during Bu administration were assessed. Indi-
idual patient medication records were reviewed and a
nivariate analysis was performed to discern whether
ny drug interactions that might signiﬁcantly alter Bu
learance and systemic exposure could be detected.
revious reports suggested that agents that alter cyto-
hrome P450-mediated metabolism, such as phenyt-
in, oral contraceptives, and metronidazole, might
nterfere with (oral) Bu clearance [21-24]. The use of
traconazole/voriconazole, estrogens/progestins, or
henytoin did not appear to alter the PK of IV Bu;
atients receiving itraconazole or voriconazole (n 
9) had a mean clearance of 116 mL/min/m2 (24),
nd an AUC of 4700 M  minute (1140), whereas
atients without antifungal therapy (n  39) had a
ean clearance of 104 mL/min/m2 (28) and a mean
UC of 4950 M  minute (1020; P NS). When
he potential importance of contraceptive therapy was
eviewed, women taking such medications (n  12)
ad a mean Bu clearance of 112 mL/min/m2 (32), and
mean AUC of 5100 Mminute (1090), whereas
hose not taking oral contraceptive agents (n  16)
ad a mean Bu clearance of 108 mL/min/m2 (28)
nd a mean AUC of 5180 M  minute (940; P 
S). Patients who started phenytoin prophylaxis the
ay before Bu (n  22) had a mean day 1 Bu clearance
f 112 mL/min/m2 (24), and a mean day 1 AUC of
590 M  minute (930), whereas those starting
henytoin immediately before Bu had a mean day 1
learance of 108 mL/min/m2 (32) and a mean day 1
UC of 4790 M  minute (1360). Similarly, the
ay 3 or 4 clearance and AUC values did not deviate
igniﬁcantly from the day 1 estimates irrespective of
hether phenytoin was started the same morning as IV
u or in the evening before chemotherapy (Table 3).
Additionally, differences in the delivery rate of the
usulfex vehicle dimethylacetamide did not change
he plasma clearance of Bu despite the fact that the
dules: IV Bu Once Daily for 4 Days and Every 6 Hours for 16 Doses
Every 6 Hr Bu
(n  47) (CV %)
Range, Daily
Administration
1.2 (20) 2.7-5.3
22.6 (21) 16.3-32.4
116 (24) 59-180
2.9 (25) 1.2-6.1ose Sche1,292 (25) 2,970-8,270
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eceiving QD dosing.
ISCUSSION
Bu, as an oral preparation, was approved for use in
954 for the palliative treatment of leukemia. At that
ime the typical doses ranged from 1 to 8 mg/day and
igure 1. a, Representative plasma concentration time plot for a pat
or 4 days. b, Representative plasma concentration time plot in a
nitially received 84 mg of intravenous Bu over 2 hours daily every 6 h
harmacokinetic parameter estimation of Bu clearance (Cl) from do
ersus time data, and the solid line represents the pharmacokinetic
ersus time curve.ittle was known about Bu PK properties. tIn the late 1970s oral Bu was introduced as a
yeloablative agent in various HSCT protocols [1-3].
u was then typically given at 1 mg/kg body weight
or total doses exceeding 1 g in adults. To facilitate the
dministration of several hundred tablets, the treat-
ent was typically divided into 4 daily doses over a
-day course. This administration schedule was arbi-
rary and selected for the sake of ease of administra-
eiving 240 mg of intravenous busulfan (Bu) over 3 hours once daily
receiving intravenous Bu every 6 hours for 16 doses; this patient
he dose was changed to 65 mg every 6 hours, with dose 3 following
e open circles represent the actual measured plasma concentration
ﬁt of the data. AUC indicates area under the plasma concentrationient rec
patient
ours. T
se 1. Th
modelion and patient convenience.
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Once-Daily IV Busulfan in Pretransplantation Conditioning Therapy 61The administration of very high doses of Bu using
n oral dosage form results in local gastrointestinal
rritation/toxicity, manifested as nausea and vomiting,
esulting in unpredictable drug loss, thus compound-
ng an already erratic systemic drug exposure due to
oor intestinal drug absorption. To circumvent the
ifﬁculties involved in oral Bu administration, a num-
er of investigators examined the relations among oral
u systemic exposure (AUC), drug-related toxicity,
nd overall treatment efﬁcacy. Subsequently, a thera-
Busulfan C m ax (µg/m l) on Days 1 and 3 or 4
Day
31
B
us
ul
fa
n 
C
m
ax
(µ
g/
m
l)
2
3
4
5
6
3 or 4
igure 2. Individual day 1 versus day 3 or 4 measured maximum
usulfan (Bu) plasma concentrations (Cmax) after 130 mg/m2 over 3
ours in 60 patients on study protocol 1. All day 3 or 4 peak
oncentrations were within 20% of the respective day 1 concen-
ration. The Cmax alterations are most likely due to differences in
rug administration time, variances in sample collection, or allow-
ble analytical error and not to nonlinear Bu disposition or excessive
rug accumulation. Most commonly, no day-to-day change in Cmax
as observed.
Protocol 1
(QD Bu)
B
us
ul
fa
n 
C
l (
m
l/m
in
/m
2 )
40
60
80
100
120
140
160
180
200
Protocol 2
(Q 6 H Bu)
116.4 ml/min/m2
111.2 ml/min/m2109.3 ml/min/m2
107.2 ml/min/m2
igure 3. Comparison of the ﬁnal busulfan (Bu) plasma clearance
Cl) estimates from study protocols 1 and 2. There was no statistical
ifference in the population clearance estimates, but a wider range
n the variability of Bu clearance in the once-daily (QD) protocol
as observed (3- versus 2-fold). The solid and dotted lines representohe population mean and median values, respectively.eutic interval for oral Bu was established, and PK-
ased dosing was introduced [6-9]. There are obvious
roblems associated with PK-guided administration of
drug whose dose-to-dose oral bioavailability varies
s much as 3-fold [26]. The inconsistent and unpre-
ictable bioavailability of oral Bu formed a basis for
eveloping an IV formulation for use in high-dose
retransplantation conditioning therapy [13-15].
Although an occasional proponent still advocates
he use of oral Bu in myeloablative therapy, the use of
he IV product has gained widespread acceptance [27].
At the time of starting IV Bu clinical trials, no
nformation was available to justify an administration
chedule different from the every 6-hour regimen
sed with oral Bu, and the early phase I-II studies with
he IV BuCy2 regimen were designed to mimic the
K experience obtained with oral Bu [3,20]. The
-hour Bu infusion schedule was selected to produce a
imilar PK proﬁle to what would, on average, be
xpected with oral Bu at a similar clinical dose [14,15].
The purpose of the present study was to examine
he PK of a new QD dosage schedule to determine the
ppropriateness and linearity of this schedule in com-
arison with the every 6-hour schedule.
We sought to determine possible differences in Bu
isposition by comparing the 2 different IV schedules.
able 2 presents a comparison of the mean (coefﬁ-
ient of variation) population Bu PK parameters, ad-
inistered as a single daily 3-hour infusion, with those
Comparative IV Busulfan AUC's Following
 Once Daily Dosing
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igure 4. Representative histogram of daily areas under the plasma
oncentration versus time curve (AUCs) achieved using the once-
aily intravenous 130 mg/m2 busulfan regimen. The mean  SD
UC for the population was 4873  1063 M  minute, and
nterpatient variability in drug exposure was considerable when
sing this ﬁxed-dose schedule; daily busulfan AUCs ranged from
900 to 8200 M  minute, with only 10 of 60 patients achieving
n AUC in the range of 5000 M  minute.btained with a 2-hour infusion given 4 times daily. As
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T. Madden et al.62emonstrated in Figures 2 and 3, the PK parameters
re nearly identical regardless of dosage schedule, in-
icating drug clearance and systemic exposure (AUC)
o be linear and dose proportional over the range of
ose rates from 0.4 mg/kg per hour (using the 0.8
g/kg every 6 hours given over 2 hours) to 1.2 mg/kg
er hour with the QD 3-hour infusion.
Further, no drug accumulation was observed over
he QD 4-day course of administration. In 10% of
atients (4 of 60), Bu was detectable in plasma samples
btained at the 21-hour postinfusion time point (day 2
f high-dose Bu) or in the trough/preinfusion samples
n day 3 or 4. The only PK parameter differing
igniﬁcantly between the 2 schedules was, as expected,
he Bu Cmax, which was dose proportional and char-
cteristically 3 times greater (on average 3.6 versus 1.2
g/mL) than that observed when using 0.8 mg/kg per
ose infused over 2 hours. This difference in Bu peak
oncentration did not appear to be associated with any
igniﬁcant increase in acute toxicity [19].
With respect to possible drug interactions that
ay signiﬁcantly alter Bu disposition, no inﬂuence of
revious use of the antifungal azole derivatives itra-
onazole or voriconazole or the concomitant of oral
ontraceptives could be conﬁrmed. We could not as-
ess the reported interactions between Bu and metro-
idazole [23] because none of our patients were taking
hat drug.
Somewhat to our surprise, no adverse interaction
etween phenytoin and Bu could be documented.
his could possibly be due to inter- and intraindi-
idual variabilities in obtained PK parameters; all our
atients received phenytoin. We did not have a (con-
rol) group of patients who did not received phenyt-
in, because our experience with phenytoin premedi-
ation for IV Bu is that it completely eliminates the
eizure risk of high-dose Bu, whereas substitution of
henytoin for benzodiazepine derivatives appears to
ower, but may not completely eliminate, the risk for
eizures. Due to the reported increase in observed Bu
learance when phenytoin premedication is used as
eizure prophylaxis for oral Bu, we altered the phe-
ytoin administration time from starting 1 day before
he ﬁrst dose of IV Bu in the ﬁrst 22 patients on this
rial to starting only 1-2 hours before the ﬁrst IV Bu
ose in the remaining 38 patients. Neither schedule
able 3. Impact of Phenytoin on Busulfan Clearance and AUC
Phenytoin Started on
Day Minus
Busulfan Dose 1 (day -6)
Clearance
(ml/min/m2)
AUC
(M  m
even (n  22) 112  24 4,590 
ix (n  38) 108  32 4,790 
-value n.s. n.s.ppeared to inﬂuence Bu PK. Our observations with bhanging the starting time of phenytoin (from 1
our to 12 hours before starting IV Bu) and the
imilarity of PK parameters obtained on days 1, 3, and
of the QD administration schedule do, however,
uggest that hepatic induction of Bu metabolism, sim-
lar to that observed with Cy [28,29], may not be a
igniﬁcant problem with IV Bu.
An alternative explanation could be that phenyt-
in, rather than altering the hepatic metabolism of Bu,
ay have its most pronounced effect(s) on area(s) of
he intestinal wall where Bu absorption occurs [30].
he latter observation would explain the apparent
ifference between our study and that of Hassan et al
24] as to the adverse interaction between phenytoin
nd the metabolism of orally administered Bu.
QD administration yielded no apparent increase
n neurotoxicity, which had been a concern because
u readily crosses the blood-brain barrier [31,32].
lthough it is not known if high (intermittent) peak
oncentrations (QD dosing) alter the clinical efﬁcacy
f Bu when compared with maintaining a more con-
istent plasma concentration as achieved with repeated
very 6-hour dosing, our comparison of clinical out-
ome in patients with AML who underwent transplan-
ation after an every 6-hour schedule (IV BuCy2)
ersus patients treated QD (IV Bu-ﬂudarabine) sug-
est that the QD regimen is at least as safe and efﬁ-
acious as the every 6-hour regimen [33].
As with the lack of drug interactions described
bove, no differences were observed in the plasma Bu
learances between the 2 groups (109 mL/min/m2 for
D versus 116 mL/min/m2 for every 6 hours) despite
delivery rate of the vehicle dimethylacetamide that
as almost 3-fold greater in patients receiving QD
osing. These data suggest that the amounts and rates
f dimethylacetamide administration have no effect on
u disposition when a daily drug dose is given over
ust 3 hours.
Thus, the demonstrated similarity in Bu PK dis-
osition regardless of administration schedule (QD
ersus every 6 hours), the lack of increased toxicity,
nd ease of administration would seem to favor a QD
V Bu schedule. This schedule would also make pa-
ient drug dose individualization for HSCT much
impler if a PK-guided approach were favored. Based
n these data we are currently evaluating the potential
Busulfan Dose 3/4 (day -4 or -3)
p-Value
Clearance
(ml/min/m2)
AUC
(M  min)
104  20 4,860  750 n.s.
100  20 5,250  980 n.s.
n.s. n.s.in)
930
1,360eneﬁt of QD Bu administration using patient PK-
g
p
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t
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1
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1
1
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1
1
1
2
2
2
2
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2
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2
Once-Daily IV Busulfan in Pretransplantation Conditioning Therapy 63uided dose adjustment to allow for (much) less inter-
atient variability in systemic Bu exposure and to
ssist in deﬁning an optimal therapeutic interval for
he Bu-ﬂudarabine combination as was previously
one for the IV BuCy2 regimen in chronic myeloge-
ous leukemia [34].
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